title: Alpha 1 adrenoceptor subtypes in the human prostate.
abstract: High affinity alpha 1 adrenoceptors have been characterized in the human prostate. The tension of prostatic smooth muscle is mediated by the alpha 1 adrenoceptor. The present study represents the first characterization of human alpha 1 adrenoceptor subtypes using radioligand receptor binding techniques. Binding studies were performed on tissue homogenates obtained from the human prostate. Competitive inhibition studies were performed in the presence of an 80 pM. 125I-Heat and 16 concentrations of unlabelled 5-methylurapidil (5 MU) or WB-4101 (10(-10) M. to 10(-5) M.). Saturation experiments were also performed with and without chloroethylclonidine (CEC, 10(-5) M.), a compound that selectively inactivates the alpha 1B subtype. The individual displacement plots for WB-4101 and 5-MU in the human prostate were consistently best fit by a 2 binding site model. WB-4101 and 5-MU exhibited a 594- and 186-fold higher affinity for the prostatic alpha 1A binding site relative to the alpha 1B binding site. The ratios of prostatic alpha 1A/alpha 1B binding sites discriminated by WB-4101 and 5-MU were 1.8 and 1.6, respectively. CEC inactivated 44% of the prostatic alpha 1 binding sites. The binding studies suggest that the dominant alpha 1 subtype in the human prostate is the alpha 1A. We are characterizing the functional properties of the alpha 1 subtypes in the human prostate.
authors.affiliation: Department of Urology, Medical College of Wisconsin, Milwaukee 53226.
authors.forename: H
authors.initials: H
authors.lastname: Lepor
authors.forename: R
authors.initials: R
authors.lastname: Tang
authors.forename: S
authors.initials: S
authors.lastname: Meretyk
authors.forename: E
authors.initials: E
authors.lastname: Shapiro
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics; D000368:Aged; D001667:Binding, Competitive; D003000:Clonidine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D004146:Dioxanes / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010627:Phenethylamines / Q000493:pharmacokinetics; D010879:Piperazines / Q000493:pharmacokinetics; D011467:Prostate / Q000737:chemistry / Q000378:metabolism*; D011942:Receptors, Adrenergic, alpha / Q000032:analysis / Q000378:metabolism*; D044024:Tetralones
chemical_list: D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D010627:Phenethylamines; D010879:Piperazines; D011942:Receptors, Adrenergic, alpha; D044024:Tetralones; C057446:5-methylurapidil; C051731:chlorethylclonidine; C048008:2-(beta-(3-iodo-4-hydroxyphenyl)ethylaminomethyl)tetralone; C010654:(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; D003000:Clonidine